medRxiv PreprintsInternational13 October 2026
Cardiomyocyte-Derived Cell-Free DNA in Hypertrophic Cardiomyopathy
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Introduction: In hypertrophic cardiomyopathy (HCM), wall stress and subclinical myocardial injury related in part to pathological hypercontractility, which in turn are associated with worse outcomes. Cell-free DNA (cfDNA) is released from cardiomyocytes (cfDNA-CM) through irreversible cellular injury and death. We investigated the feasibility of quantifying cfDNA-CM and its relationship to HCM patient characteristics. Methods: We analyzed 57 plasma samples from stable patients with HCM and 10 plasma samples from patients with acute myocardial infarction (AMI). Plasma cfDNA was isolated from bo
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Language eligibility criteria and enrolled racial and ethnic composition in US clinical trials: a cross-sectional study13 October 2026
- Contrasting Patterns of Cortical Volume Change in First-Episode Schizophrenia-Spectrum Psychosis13 October 2026
- Atrial fibrillation begets atrial fibrillation - serum-driven amplification of atrial electrical instability13 October 2026
- Vascular Remodelling in Idiopathic Nephrotic Syndrome with Administration of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers13 October 2026
- Association of childhood experiences with wellbeing and flourishing outcomes in Indian adults: Evidence from the India Sample of the Global Flourishing Study (GFS)13 October 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.